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Mitochondria in the Cerebral and 
Cerebellar Cortex in Alzheimer’s 




Alzheimer’s disease remains the main cause of dementia in advanced age 
worldwide. Among the etiopathological background of the disease mitochondrial 
alterations may play a crucial role, given that they are closely related to metabolic 
and energy deficiency in neurons, glia, and endothelial cells in Alzheimer’s disease 
and other neurodegenerative disorders. In a series of morphological and mor-
phometric studies of mitochondria in the cerebrum and the cerebellar cortex in 
Alzheimer’s disease, by electron microscopy, we described marked morphological 
and morphometric alterations. The most frequent ultrastructural alterations of 
the mitochondria consist of disruption of the cristae, accumulation of osmiophilic 
material, and marked changes of shape and size in comparison with the normal 
controls. Mitochondrial alterations were particularly prominent in dendritic profiles 
and dendritic spines. The ultrastructural study of a substantial number of neurons 
in the cerebellum revealed that mitochondrial alterations do not coexist, as a rule, 
with the typical Alzheimer’s pathology, such as cytoskeletal alterations, amyloid 
deposits, and tau pathology, though they are frequently observed coexisting with 
alterations of the cisternae of the Golgi apparatus. Therapeutical regimes targeting 
mitochondria may be beneficial in early cases of Alzheimer’s disease.
Keywords: Alzheimer’s disease, Mitochondria, Electron microscopy, Oxidative stress 
Treatment, cerebrum, cerebellum
1. Introduction
Alzheimer’s disease is the main causative factor of presenile and senile dementia 
[1] involving a large number of potential pathogenetic mechanisms, which for years 
was extinguishing the mental capacities, affecting seriously the cognition of the 
patients and leading to a tragic epilogue of the life with many social, economic and 
humanitarian consequences.
The phenomenology of familial or sporadic Alzheimer’s disease is the final act 
of a drama, which gradually was causing selective and progressive neuronal loss 
[2], extensive synaptic alterations [3, 4], progressive neurofibrillary degeneration 
[5] resulting in intracellular accumulation of hyperphosphorylated tau protein [6], 
in the form of neurofibrillary tangles, with a parallel accumulation of extracellular 
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deposits of Aβ peptide forming neuritic plaques with an obvious microglial 
involvement [7]. The accumulation of the Aβ peptide as the main causative factor 
in Alzheimer’s disease has been the core of the amyloid cascade hypothesis, which 
gained a considerable reputation, attempting to interpret all the pathological 
phenomena in the stream of the morphological and functional disintegration in 
Alzheimer’s disease [8].
However, a substantial body of evidence underlines the increasing differentia-
tion from the amyloid hypothesis [9] and emphasizes the crucial role that mito-
chondrial alterations and dysfunction may play in the pathogenesis of Alzheimer’s 
disease and other neurodegenerative disorders [10–14].
Mitochondria are double membraned organelles, which are the cardinal energy 
suppliers of the eukaryotic cells by generating ATP, via oxidative phosphoryla-
tion. Mitochondria have their circular, double-stranded DNA (mtDNA), encoding 
thirteen proteins essential for oxidative phosphorylation [15], which is continuously 
processed by five protein complexes of the respiratory chain (complexes I-V).
Mitochondrial DNA plays reasonably a crucial role in the homeostatic mecha-
nisms of the cell, by providing the essential energetic background for most of the 
cellular procedures. Moreover, mitochondrial DNA is also involved in a significant 
number of functional pathways, concerning cellular signaling by generating 
reactive oxygen species (ROS) synthesis of neurotransmitters at the presynaptic 
terminals. It is reasonable, that based on their multidimensional activity, mitochon-
dria would be versatile structures, continuously renewed by fusion and fission [16] 
and frail to degradation thru mitophagy [17, 18].
Mitochondrial morphology is mainly modulated by the neurofilaments and 
microtubules, given that mitochondria are mostly transported along the microtu-
bules [19], expressing at the same time an immediate adaptation to energetic needs 
and immune responses of the cells [20]. The fact that mitochondria have an anti-
viral signaling protein (MAVS), in connection to the outer membrane, emphasizes 
their importance in activating immune reactions [21] and participating in antiviral 
responses [22].
In Alzheimer’s disease, the mitochondrial alterations, are responsible for the 
reduced energy production, oxidative stress, and the inflammatory reactions [23], 
which are among the early phenomena of the disease [24, 25], in the broad spec-
trum of the functional and morphological alterations [26, 27], which occur affect-
ing progressively the neuronal and synaptic integrity.
Mitochondrial alterations resulting in substantial oxidative stress have been 
described in a considerable number of neurodegenerative diseases [28–30], a fact 
which emphasizes the importance of mitochondria morphological and functional 
integrity in the normal life and long survival of neurons and glial cells. Oxidative 
stress triggers also the initiation of a real cascade of pathological phenomena, 
including the modulation of innate immunity, which provokes a further mitochon-
drial dysfunction, given that mitochondria and mtDNA are very sensitive to oxida-
tive stress [31, 32]. Besides, the association of oxidative stress with the increased 
accumulation of calcium ions [33], would also be considered among the principal 
causes of apoptosis [34].
Oxidative stress in Alzheimer’s disease is mostly related to amyloid β (Αβ) accu-
mulation in the neocortex [35, 36], which is a phenomenon playing a crucial role in 
the pathogenetic process of Alzheimer’s disease [37]. The mitochondrial dysfunc-
tion has culminated with the existent beta-Amyloid toxicity in connection with 
the decreased rate of glycolysis [38] and the inhibition of the mitochondrial cyto-
chrome c oxidase by a dimeric conformer of Aβ42 [39, 40]. Besides, the increasingly 
synthesized reactive oxygen species (ROS), aggravate the mitochondrial dysfunc-
tion, increase the mitochondrial Ca load [41], initiating mitophagy eventually [42].
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However, mitochondrial ROS in low levels may play a positive role acting as 
second messengers and controlling several physiological processes [43]. Also, ROS 
are considered as being responsible for NLRP3 inflammasome activation [44, 45].
In excessive ROS synthesis the endogenous antioxidant defense system, such 
as superoxide dismutase, glutathione peroxidase, superoxide reductase, catalase, 
are unable to counteract the ROS’s vulnerability. It is also significant, that cytosolic 
mtDNA may activate the NLRP3 inflammasome increasing, even more, the inflam-
matory reactions [46].
Also, the hyperphosphorylated tau protein interacts with the voltage-dependent 
anion channel 1 (VDAC1) protein, affecting mitochondrial pores and deteriorat-
ing mitochondrial activity [47]. In a parallel way, caspase-cleaved tau impairs 
mitochondrial dynamics in Alzheimer’s disease [48]. Therefore, it seems that the 
convergence of amyloid and tau pathology on mitochondria impair synergistically 
the mitochondrial function and exacerbate oxidative stress [49].
From the morphological point of view, the shape and the size of mitochondria 
are highly variable depending upon the fusion and fission processes, which are 
regulated by mitofusins (Mfn-1 and Mfn- 2) and optic atrophy protein- 1 (OPA- 1) 
[50]. From the morphometric point of view, the number of the mitochondria varies 
in the soma and neuronal processes, according to the energy state of the cell, given 
that they are transported and accumulated to regions where energy demands and 
ATP consumption are particularly high [51].
In Alzheimer’s disease, morphological alterations of the mitochondria have been 
described [11, 52, 53] even in the early cases of the disease [11] coinciding with 
dendritic and synaptic pathology [54]. Some evidence suggests that the interaction 
of mitochondrial fission protein DRP- 1 with the Aβ peptide and the hyperphos-
phorylated tau protein results in mitochondrial fragmentation increasing therefore 
the mitochondrial damage [55].
Mitochondrial trafficking in Alzheimer’s disease plays also an important role in 
abnormal mitochondrial positioning and accumulation. Mitochondrial motility is 
controlled normally by kinesin and dynein which are powered by ATP hydrolysis, 
whereas the immobilization of mitochondria in places of high energy consumption 
is controlled by syntaphilin [56]. In Alzheimer’s disease, the hyperphosphorylated 
tau protein at AT8 sites (ROS), as by-products of the respiration chain, aggravates 
the mitochondrial dysfunction, increases the mitochondrial Ca load and the neuro-
nal oxidative stress [41], initiating mitophagy eventually [42].
However, mitochondrial ROS in low levels may play a positive role acting as 
second messengers and controlling several physiological processes [43]. I addition, 
ROS are considered as being responsible for NLRP3 inflammasome activation 
[44, 45].
On the contrary, in excessive ROS synthesis the endogenous antioxidant defense 
system, is unable to counteract the ROS’s vulnerability. It is also significant the fact, 
that cytosolic mtDNA may activate the NLRP3 inflammasome increasing, even 
more, the inflammatory reactions [46].
Besides the hyperphosphorylated tau protein interacts with the voltage-depen-
dent anion channel 1 (VDAC1) protein, affecting mitochondrial pores and deterio-
rating mitochondrial function [47]. In a parallel way, caspase-cleaved tau impairs 
mitochondrial dynamics in Alzheimer’s disease [48]. Therefore, it seems that the 
convergence of amyloid and tau pathology on mitochondria impair synergistically 
the mitochondrial activity and exacerbate oxidative stress [49].
From the morphological point of view, the shape and the size of mitochondria 
are highly variable depending upon the fusion and fission processes, which are 
regulated by mitofusins (Mfn-1 and Mfn-2) and optic atrophy protein-1 (OPA-1). 
[50]. From the morphometric point of view, the number of the mitochondria varies 
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in the soma and neuronal processes, according to the energy state of the cell, given 
that they are transported and accumulated to regions where energy demands and 
ATP consumption are particularly high [51].
In Alzheimer’s disease, morphological alterations of the mitochondria have 
been described [11, 52, 53] even in the early case of the disease [11] coinciding with 
dendritic and synaptic pathology [54]. Some evidence suggests that the interaction 
of mitochondrial fission protein DRP- 1 with the Aβ peptide and the hyperphos-
phorylated tau protein results in mitochondrial fragmentation increasing therefore 
the mitochondrial damage [55].
Mitochondrial trafficking in Alzheimer’s disease plays also an important role in 
abnormal mitochondrial positioning and accumulation. Mitochondrial motility is 
controlled normally by kinesin and dynein which are powered by ATP hydrolysis, 
whereas the immobilization of mitochondria in places of high energy consumption 
is controlled by syntaphilin [56].
In Alzheimer’s disease, the hyperphosphorylated tau protein at AT8 sites [57] 
may impede the mitochondrial transport via microtubules, leading to improper 
distribution of mitochondria in giant spines and abnormal synapses [58, 59]. 
In parallel, oligomers of Ab peptide impair mostly the anterograde movement 
of mitochondria [60], increasing the number of stationary mitochondria in the 
neuronal soma.
The observation that mitochondrial abnormalities occur as an early phenom-
enon in Alzheimer’s disease [11], supports the hypothesis that mitochondrial 
degeneration plays a primal role in Alzheimer’s disease pathogenetic procedure, 
inducing a chain of pathological alterations involving tau and amyloid pathology. 
Morphological alteration of mitochondria, as well as abnormal interconnections of 
mitochondria with neurofilaments and microtubules, have been described at the 
level of electron microscopy in dendrites, axons, and synaptic components, a fact 
which emphasizes the close association of mitochondrial pathology with the broad 
pattern of the morphological changes in Alzheimer’s disease [61, 62].
In this study, which is an extensive observation on electron microscopy, we 
attempted to describe the morphological alterations of mitochondria in early cases 
of Alzheimer’s disease in neurons from various areas of the cerebral and cerebellar 
cortex, proposing also therapeutic approaches in the initial stages of Alzheimer’s 
disease, based on the existing mitochondrial pathology.
2. Material and methods
2.1 Material
For describing the morphological alterations of neuron’s organelles in early cases 
of Alzheimer’s disease by electron microscopy we focused our observation mostly 
on the mitochondria in twenty-two cases, fourteen men and eight women, aged 
52–87 years, who fulfilled all the clinical, neuropsychological [63] and laboratory 
diagnostic criteria of Alzheimer’s disease.
The brains were derived from patients, who died accidentally 24 to 46 months 
following the clinical diagnosis of Alzheimer’s disease. Additional 15 brains, mac-
roscopically intact derived from apparently healthy persons of parallel age with the 
patients, were used as normal controls.
Multiple samples from many areas of the brain, namely from the prefrontal 
area of the frontal lobe, the frontal pole, the acoustic cortex, the visual cortex, the 
parietal lobe, the insula, the vermis of the cerebellum, and the cerebellar hemi-
spheres were taken in a room temperature of 40 C., 4 to 5 hours after death. Samples 
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also from the hippocampus, the hypothalamus, the mammillary bodies, the locus 
coeruleus, the red nucleus, the globus pallidus were excised under the same condi-
tions, processed for electron microscopy, and the findings were described and in 
previous reports.
2.2 Method
All the specimens were immediately immersed in Sotelo [64] fixing solution, 
for three hours, then post-fixed in osmium tetroxide for 30 min. and dehydrated in 
graded alcohol solutions and propylene oxide. Thin sections were cut in a Reichert 
ultratome, contrasted, with uranyl acetate and lead citrate, and studied in electron 
microscopes Elmiscope 1 and Zeiss 9As. All the methodological and technical details 
of the preparation of the specimens for electron microscopy have been described 
extensively in our previous reports [65, 66].
Following the morphological description of the mitochondria, we proceeded 
also to morphometric estimations on micrographs of a standard magnification of 
56.000X.
The methodology of the morphometric estimation of the mitochondria and 
the statistical analysis of the data have been extensively described in our previous 
reports [11, 65].
3. Results
The mitochondria in cases of Alzheimer’s disease demonstrate a wide variation 
of size and shape in comparison with the mitochondria of normal control brains 
(Figure 1). We noticed that numerous mitochondria were small round or elongated, 
particularly those which were inside the dendritic profiles or the synaptic terminals 
(Figure 2).
Figure 1. 
Mitochondrion of a Purkinje cell of the cerebellum of 75 years old man unremarkable neurologically.  
(Mag. 72,000 X).
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Figure 2. 
Mitochondrial alterations in synaptic terminals and dendritic profiles in the molecular layer of the cerebellum 
of a male patient aged 75 years, suffered from Alzheimer’s disease. The disruption of the mitochondrial cristae 
is obvious. Electron micrograph (Mag.68,000 X).
Figure 3. 
In the majority of the synaptic profiles the mitochondria are elongated demonstrating an impressive 
polymorphism, concerning the arrangement of the cristae. Mitochondria in a synaptic profile in the molecular 
layer of the cerebellum of a male patient aged 68, who suffered from Alzheimer’s disease. Electron micrograph 
(Mag. 68,000X).
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A substantial number of mitochondria show disruption of the cristae, though 
others include osmiophilic material [10, 11, 13]. In the majority of the synaptic 
profiles, the mitochondria showed an impressive polymorphism, concerning the 
pattern and the arrangement of the cristae (Figure 3). That polymorphism was 
particularly obvious in dendritic profiles in acoustic and visual cortices, where mor-
phological alterations of the mitochondria coexisted frequently with the fragmenta-
tion of the Golgi apparatus (Figure 4).
The ultrastructural study of the cerebellar cortex, in the vermis and the hemi-
spheres, revealed impressive mitochondrial polymorphism in the soma of the 
neurons, the dendritic profiles (Figure 5), as well as in the axons and the synaptic 
terminals (Figure 6) [66, 67].
Besides, the electron microscopy study revealed that morphological alterations 
are frequently seen in neurons of the prefrontal cortex, which included mostly 
small round mitochondria, with an abnormal arrangement of the cristae (Figure 7). 
Abnormal polymorphic mitochondria in association with the fragmentation of the 
Golgi apparatus were also observed in the Purkinje cells of the cerebellar cortex in 
the vermis and the hemispheres [68], in the stellate cells of the molecular layer of 
the cerebellar cortex (Figure 8), as well as in a substantial number of neurons of the 
prefrontal cortex [69].
By the morphological analysis of the mitochondria in the cortex of the brain 
hemispheres in Alzheimer’s disease, it was realized that mitochondrial pathology 
was associated as a rule with dendritic and spinal pathology [70].
From the morphometric point of view, the ellipsoid mitochondria in normal 
controls appear to have an average diameter of 650 ± 250 nm and a mean axial ratio 
of 1.9 ± 0.2. The round or global mitochondria in normal controls appeared to have 
a mean mitochondrial radius of 350 nm.
Figure 4. 
Mitochondrial polymorphism is obvious in neurons of the acoustic cortex, where morphological alterations 
of the mitochondria coexist frequently with the fragmentation of the Golgi apparatus. Electron micrograph 
of a neuron from the acoustic cortex of a female patient, who suffered from Alzheimer’s disease at the age of 
73 years, (Mag. 28, 000 X).
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In the brains of patients who suffered from Alzheimer’s disease, the ellipsoid 
mitochondria of the neurons appeared to have an average diameter of 510 ± 250 nm 
and a mean axial ratio of 1.7 ± 0.2. The round mitochondria have had a mean 
radius of 280 nm. Also, the round mitochondria appeared to have a mean radius 
of 350 nm.
Figure 5. 
Very elongated mitochondrion in a dendritic profile in the mocelular layer of the vermis of a male patient aged 
63 years, who suffered from Alzheimer’s disease in the early stages. Electron micrograph (Mag. 128,000 X).
Figure 6. 
Fragmentation of the cristae and impressive polymorphism of mitochondria in dendritic spines in the cortex 
of the cerebellar hemispheres of a male patient who suffered from Alzheimer’s disease at the age of 75 years. 
Electron micrograph. Mag.135.000X).
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Figure 7. 
Small mitochondria with abnormal arrangement of the cristae in a neuron from the prefrontal cortex of a 
male patient aged 75 years, who suffered from Alzheimer’s disease in the early stages. Electron microgram  
(Mag. 28,000 X).
Figure 8. 
Morphological alterations of mitochondria, coexist frequently with fragmentation of Golgi apparatus. Small 
compact mitochondria and fragmented cisternae of Golgi apparatus in the soma of an interneuron (stellate 
cell) of the molecular layer of the cerebellum of a male patient aged 63 years, who suffered from Alzheimer’s 
disease in the early stages. Electron micrograph (Mag. 28,000 X).
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4. Discussion
The morphological alteration of the mitochondria, which was extensively 
observed in the cortex of the brain hemispheres, the vermis and the hemispheres 
of the cerebellum pleads in favor of a generalized mitochondrial dysfunction in 
Alzheimer’s disease, which would be associated with wide neuronal loss, impaired 
axoplasmic flow, dendritic pathology, and marked synaptic and spinal alterations, 
which would be seriously affecting the mental faculties of the patients [71].
The defective mitochondria in Alzheimer’s neurons may not supply adequate 
levels of Adenosine Triphosphate (ATP), which is very important at the synaptic 
level for normal neural communication. It is expectable that the low levels of cellu-
lar ATP at nerve terminals may lead to extensive loss of synapses or cause defective 
function in the majority of them [72]. Besides, oxidative stress decreases the rate of 
choline recycling at the synapses, leading to Ach deficiency [73].
Many morphological alterations of AD could be linked to mitochondria changes 
since blockage of mitochondrial energy production shifts amyloid-protein precur-
sor metabolism to the production of more amyloidogenic forms of amyloid [74]. 
Thus it induces the production of A68 antigen [75, 76], and activates the mitogen-
activated protein kinase pathway [77–79].
Also, inadequate energy production impairs the mitochondrial motility in the 
soma, the axons, and the dendritic branches of neurons, resulting in trafficking 
jams aggravating even farther the mitochondrial function [80].
Accumulation also of transmembrane-arrested AβPP may block protein 
translocation, affecting, even more, the mitochondrial function. In a parallel way, 
the accumulated Aβ peptide in the mitochondrial membrane may be transported 
from the cytosol via mitochondrial translocases, which are located either in the 
outer or the inner mitochondrial membranes. Moreover, the Aβ peptide interacts 
with an Aβ-binding dehydrogenase (ABAD) in the mitochondria of patients 
suffering from Alzheimer’s disease as well as in transgenic mice, suggesting that 
ABAD is closely related, to mitochondrial toxicity [81]. Overexpression of ABAD 
can increase oxidative stress, accelerating, therefore, neuronal death. However, 
ABAD may play an important role in the oxidation of alcohols, facilitating the 
reduction of aldehydes and ketones, and decreasing subsequently the metabolic 
stress [82].
The Aβ-peptide may interact with cyclophilin D (CypD), a component of the 
mitochondrial transition pore, inducing cytotoxicity [83]. Moreover, morphological 
alterations of mitochondria in AD may be related to the increased mitophagy, which 
is proved by the accumulation of mitochondrial autophagic elements in neurons 
of AD patients [84]. In AD the PINK1-Parkin-dependent mitophagy pathway may 
also be involved in mitochondrial pathology [85]. The prompt clearance of dam-
aged mitochondria may result in increasing the density of normal mitochondria 
in dendrites and synaptic terminals, which is a fact ameliorating the synaptic 
function [86].
5.  Suggestions on the treatment of Alzheimer’s disease on the basis  
of mitochondrial pathology
Concerning the treatment of Alzheimer’s disease, we would underline that the 
preclinical stage is frequently overlooked, because it might be characterized as mild 
cognitive impairment, with considerable consequences on the course and the treat-
ment of the disease.
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Following the clinical manifestation of the disease and the diagnostic docu-
mentation, many therapeutic regimes have been applied without any substantial 
beneficial effect. In the decade 2002–2012 more than 240 drugs, mostly cholinester-
ase inhibitors, and NMDA receptor antagonists, have been tried for the treatment 
or even the amelioration of the quality of life in patients suffered from AD [87, 88], 
without any obvious effectiveness. Besides, any strategy attempting to reduce the 
amyloid aggregations in the brain, despite the numerous trials, was not fruitful [89].
Based on mitochondrial pathology, in the limits of the broad pathogenetic spec-
trum of Alzheimer’s disease, the mitochondria may be considered as the potential 
therapeutic targets, which might inhibit the stream of the neuropathological altera-
tions and impede the clinical deterioration of the patients.
Strategists protecting the mitochondria in Alzheimer’s disease would include the 
administration of efficient antioxidant factors, which might counteract the oxida-
tive stress, and decrease ROS production [90].
Natural antioxidants that could penetrate the blood–brain barrier may be 
effective in the initial stage of Alzheimer’s disease. The administration of  
Vitamins C, E, beta carotene, glutathione, Coenzyme Q10, epigallocatechin 
gallate, curcumin, lipoic acid, Ginkgo biloba, resveratrol, pramipexole, 
N-acetylcysteine, latrepirdine, idebenone, ubiquinone may reduce the production 
of ROS, suppressing the oxidative stress.
The tetracyclin Minocycline prevents also oxidative stress and controls the 
release of cytochrome c from mitochondria, inhibiting the activation of caspase-3 
and the subsequent apoptosis [91], being therefore quite effective in the treatment 
of AD [92].
In a parallel way, the adaptation of the Cretic or Mediterranean diet, combined 
with frequent proper physical exercise, in the early stages of the disease, may 
stabilize the mental capacities of the patients for a non-limited period and postpone 
the tragic epilogue of the disease. Besides, prolonged administration of pyruvate 
may improve the working memory in the preclinical stage AD [93].
We have realized, by a detailed clinical and neuropsychological evaluation of 
a considerable number of patients, who suffered from Alzheimer’s disease in the 
initial stages, that the quotidian administration of Riboflavin (Vit.B2) in a dose 
of 100–200 mg per day would play a positive role in inhibiting the course of the 
disease and stabilizing the mental faculties of the patients (Baloyannis, unpublished 
data). It is known that riboflavin serves as a flavoprotein precursor in the synthesis 
of flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) [94, 95], 
which are electrochemically-active factors involved in regulatory pathways of mito-
chondria. Riboflavin serves also as a cofactor in fatty acid β-oxidation. Riboflavin 
deficiency may be involved in the pathogenetic mechanism of several neurode-
generative disorders [96, 97]. Thus, riboflavin supplementation may be enriching 
the therapeutical regime in some non-uncommon neurological conditions [98, 99] 
including Alzheimer’s disease [100].
At the experimental level, mitochondrial-targeted molecules, such as MitoQ 
and Szeto- Schiller (SS) peptides have been used for increasing the concentration 
of antioxidants into mitochondria [101]. MitoQ exerts direct antioxidant action by 
scavenging superoxide, peroxyl, and peroxynitrite ROS. It seems also to contribute 
effectively, enhancing the mitochondrial biogenesis in a transgenic mouse model of 
Alzheimer’s disease [102, 103].
The fact that the interaction of ABAD with the Aβ peptide may increase the toxic 
effects upon the mitochondria, suggests that ABAD inhibitors such as AG18051 
[104] and RM-532-46, might be applied as therapeutic factors in the treatment of 
patients who suffer from AD.
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Also, a decrease of the CypD in AD relieves the toxic effect that Aβ imposes 
on the mitochondria and may ameliorate the mental condition of the patients 
[83] improving the synaptic function by the restoration of mitochondrial activity 
[105]. Also, Oligomycin-sensitivity conferring protein (OSCP) is a crucial subunit 
of mitochondrial F1Fo ATP synthase, essential for its structural stability [106]. 
In Alzheimer’s disease, deregulation of mitochondrial F1FO-ATP synthase was 
described [107]. It is reasonable to be hypothesized that OSCP would be a positive 
factor in the treatment of early cases of Alzheimer’s disease.
The administration of factors that may regulate mitophagy, and cardiolipin-
induced mitophagy [108] such as NAD+ precursors, actinonin (AC), spermidine, 
urolithin A (UA), rapamycin, and doxycycline may also control the mitochon-
drial unfolded protein response (UPRmt), reducing the Aβ accumulation and 
 proteotoxicity [109].
The administration of metformin can increase also the resistance of the mito-
chondria to oxidative stress [110]. The supplementation with nicotinamide may be 
beneficial in the early stages of Alzheimer’s disease improving the cognition of the 
patients [111].
The administration of mitochondrial uncoupling factors such as 2, 4-dinitrophe-
nol (DNP) may be effective too, protecting mitochondria and stabilizing neuronal 
function in animal models of AD [112, 113]. Besides, the administration of galan-
thamine hydrochloride may control autophagy [114], as was noticed by the decrease 
of autophagosome formation.
Recently it was found that vacuole membrane protein 1 (VMP1), which is 
located in the endoplasmic reticulum (ER), may play a crucial role in mediating 
autophagy [115] and controlling mitochondrial morphology, given that numerous 
mitochondria are damaged upon VMP1 deficiency [116]. It must be underlined 
that autophagy is an important mechanism for maintaining cell homeostasis by 
liberating the cell from the accumulation of misfolded proteins and other undesired 
elements [117].
Erythropoietin (EPO) [118], is a cytokine essential for erythroid development 
and maturation, playing a beneficial role in progressive degenerative diseases [119] 
exercising among others a protective effect on mitochondrial morphology, facilitat-
ing the activity of cellular bioenergetics [120].
Furthermore, the relation between mitochondria and endoplasmic reticulum 
(ER) referred to as the MAMs [121, 122], which are enriched in presenilin proteins 
[123], may play an important role in the pathogenetic cascade of Alzheimer’s 
disease, given that they are involved in the production of intracellular Aβ [124], 
and play also a substantial role in cellular Calcium homeostasis [125, 126] and lipid 
transport between the endoplasmic reticulum and the mitochondria [127]. A deep 
understanding of MAMs involvement in the pathogenesis of AD may provide new 
ways of therapeutic approach in the early stages of AD.
The protection of mitochondria by the Szeto-Schiller (SS) peptides, particularly 
the SS31 tetra-peptide [128, 129], which is targeted to the inner mitochondrial mem-
brane, revealed that it may have protective effects against mitochondrial and synaptic 
toxicities in APP transgenic mice [130], reducing also mitochondrial fragmentation 
and increasing mitochondrial transport in AD neurons [131].
Mitochondrial biogenesis is decreased in AD [132] due to the decrease of the 
rate of mitochondrial division, a fact that aggravates substantially the mitochon-
drial dysfunction [133]. Supporting mitochondrial biogenesis may contribute 
to the therapeutic confrontation of AD [134]. Therefore, the administration of 
Nicotinamide riboside [135, 136], as well as of pioglitazone or rosiglitazone may 
improve the mental condition of the patients [137, 138].
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In experimental models, the administration of melatonin contributed consider-
ably to improving the biogenesis of mitochondria [139]. Besides, melatonin inhibits 
amyloidogenesis and promotes the non-amyloidogenic pathway [140], restoring 
also the equilibrium of the Ca2+ [141]. Recent neuropathological findings revealed 
that melanin-concentrating hormone (MCH) neurons in the lateral hypothalamic 
area of patients who suffer from AD undergo degeneration, a fact that may interpret 
the frequent sleep and metabolic disorders of the patients [142].
Also, it was observed, that the Zinc ion (Zn2+) supplementation in experimental 
models, contributed to ameliorating the mitochondrial function by the restoration 
of BDNF levels and improving cognition, although it might have negative effects on 
some cells lines [143].
Α substantial body of evidence suggests that among the causative factors in the 
multifactorial labyrinth of AD, the hemodynamic disturbances resulting in chronic 
hypoperfusion of the brain [144–147] play also a crucial role in attenuating the 
mitochondrial dysfunction [148] and aggravating subsequently the mental condi-
tion of the patients [149]. The improvement of the blood supply of the brain should 
be among the principal therapeutic strategists in AD.
Mitochondrial alterations may be estimated as potential biomarkers, which 
would provide a prognostic response to treatment [150]. Mitochondria may be 
considered as a significant strategic point for therapeutical interventions in early 
cases of Alzheimer’s disease.
6. Conclusions
Mitochondrial alterations may play an important role in the pathogenesis of 
Alzheimer’s disease. In early cases of Alzheimer’s disease marked morphological 
and morphometric alterations have been described by electron microscopy in vari-
ous areas of the brain and the cerebellum.
The morphological alterations of the mitochondria seem to be independent 
of Alzheimer’s pathology, given that they are observed in areas without or with 
minimal neuritic plaques or tau pathology.
Mitochondria may be considered as a significant strategic point for therapeutical 
interventions in early cases of Alzheimer’s disease.
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